Article

 

Pseudoprogression of Glioblastoma after Chemo- and Radiation Therapy: Diagnosis by Using Dynamic Susceptibilityweighted Contrast-enhanced Perfusion MR Imaging with Ferumoxytol versus Gadoteridol and Correlation with Survival Public Deposited

No preview available

Download the file

https://ir.library.oregonstate.edu/concern/articles/wh246t03h

Descriptions

Attribute NameValues
Creator
Abstract
  • This file has been removed from the repository due to a DMCA Takedown Notice.
  • - - - -
  • [Purpose] To compare gadoteridol and ferumoxytol for measurement of relative cerebral blood volume (rCBV) in patients with glioblastoma multiforme (GBM) who showed progressive disease at conventional magnetic resonance (MR) imaging after chemo- and radiation therapy (hereafter, chemoradiotherapy) and to correlate rCBV with survival. [Materials and Methods] Informed consent was obtained from all participants before enrollment in one of four institutional review board–approved protocols. Contrast agent leakage maps and rCBV were derived from perfusion MR imaging with gadoteridol and ferumoxytol in 19 patients with apparently progressive GBM on conventional MR images after chemoradiotherapy. Patients were classified as having high rCBV (>1.75), indicating tumor, and low rCBV (≤1.75), indicating pseudoprogression, for each contrast agent separately, and with or without contrast agent leakage correction for imaging with gadoteridol. Statistical analysis was performed by using Kaplan-Meier survival plots with the log-rank test and Cox proportional hazards models. [Results] With ferumoxytol, rCBV was low in nine (47%) patients, with median overall survival (mOS) of 591 days, and high rCBV in 10 (53%) patients, with mOS of 163 days. A hazard ratio of 0.098 (P = .004) indicated significantly improved survival. With gadoteridol, rCBV was low in 14 (74%) patients, with mOS of 474 days, and high in five (26%), with mOS of 156 days and a nonsignificant hazard ratio of 0.339 (P = .093). Five patients with mismatched high rCBV with ferumoxytol and low rCBV with gadoteridol had an mOS of 171 days. When leakage correction was applied, rCBV with gadoteridol was significantly associated with survival (hazard ratio, 0.12; P = .003). [Conclusion] Ferumoxytol as a blood pool agent facilitates differentiation between tumor progression and pseudoprogression, appears to be a good prognostic biomarker, and unlike gadoteridol, does not require contrast agent leakage correction.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Gahramanov, S., Muldoon, L. L., Varallyay, C. G., Li, X., Kraemer, D. F., Fu, R., . . . Neuwelt, E. A. (2013). Pseudoprogression of glioblastoma after chemo- and radiation therapy: Diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology, 266(3), 842-852. doi: 10.1148/radiol.12111472
Journal Title
Journal Volume
  • 266
Journal Issue/Number
  • 3
Academic Affiliation
Keyword
Rights Statement
Funding Statement (additional comments about funding)
  • This research was supported by the National Institutes ofHealth (grants 5 R01 NS053468, 5 R01 CA137488, 3 R01CA137488-15S1, and 5 R01 NS044687).
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Made available in DSpace on 2013-04-01T17:56:49Z (GMT). No. of bitstreams: 1 KraemerDaleFPharmacyPseudoprogressionGlioblastomaAfter.pdf: 2769325 bytes, checksum: fbbbe6fc0af37c4c51765775a8d92b4b (MD5) Previous issue date: 2013-03
  • description.provenance : Submitted by Deborah Campbell (deborah.campbell@oregonstate.edu) on 2013-04-01T17:09:35Z No. of bitstreams: 1 KraemerDaleFPharmacyPseudoprogressionGlioblastomaAfter.pdf: 2769325 bytes, checksum: fbbbe6fc0af37c4c51765775a8d92b4b (MD5)
  • description.provenance : Approved for entry into archive by Deborah Campbell(deborah.campbell@oregonstate.edu) on 2013-04-01T17:56:49Z (GMT) No. of bitstreams: 1 KraemerDaleFPharmacyPseudoprogressionGlioblastomaAfter.pdf: 2769325 bytes, checksum: fbbbe6fc0af37c4c51765775a8d92b4b (MD5)

Relationships

Parents:

This work has no parents.

Items